// App-Quantinova.ai

LB0002 (2022) : BARICITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, WITHDRAWAL, EFFICACY AND SAFETY STUDY

Researchers

Presenter

  • A. Ramanan

Principal Investigators

  • P. Quartier

  • N. Okamoto

  • G. Meszaros

  • J. Araujo

  • Z. Wang

  • R. Liao

  • B. Crowe

  • X. Zhang

  • R. Decker

  • S. Keller

  • H. Brunner

  • N. Ruperto

Medical Centers

  • Bristol Royal Hospital for Children, Bristol Medical School, Bristol, United Kingdom

  • Necker Hospital, Pediatric Immunology, Hematology and Rheumatology, Paris, France

  • Ōsaka Rōsai Hospital, Pediatrics, Sakai, Japan

  • Eli Lilly and Company Corporate Center, GPS Medical-Autoimmune & Product Safety, Indianapolis, United States of America

  • Eli Lilly and Company Corporate Center, Statistics, Indianapolis, United States of America

  • Eli Lilly and Company Corporate Center, Statistics, Indianapolis, United States of America

  • Eli Lilly and Company Corporate Center, Statistics-Immunology, Indianapolis, United States of America

  • Eli Lilly and Company Corporate Center, PK/PD and Pharmacometrics, Indianapolis, United States of America

  • Cincinnati Children's Hospital Medical Center, Scientific Director for the Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, United States of America

  • I.R.C.C.S. Giannina Gaslini, Senior Scientist for the Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy

Locations

  • United Kingdom

  • France

  • Japan

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03773978

Sponsors

  • Eli Lilly and Company

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved